GB202212641D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB202212641D0
GB202212641D0 GBGB2212641.1A GB202212641A GB202212641D0 GB 202212641 D0 GB202212641 D0 GB 202212641D0 GB 202212641 A GB202212641 A GB 202212641A GB 202212641 D0 GB202212641 D0 GB 202212641D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2212641.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Priority to GBGB2212641.1A priority Critical patent/GB202212641D0/en
Publication of GB202212641D0 publication Critical patent/GB202212641D0/en
Priority to PCT/EP2023/073850 priority patent/WO2024047135A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
GBGB2212641.1A 2022-08-31 2022-08-31 Novel compounds Ceased GB202212641D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2212641.1A GB202212641D0 (en) 2022-08-31 2022-08-31 Novel compounds
PCT/EP2023/073850 WO2024047135A1 (en) 2022-08-31 2023-08-30 Substituted heterocycles as ras inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2212641.1A GB202212641D0 (en) 2022-08-31 2022-08-31 Novel compounds

Publications (1)

Publication Number Publication Date
GB202212641D0 true GB202212641D0 (en) 2022-10-12

Family

ID=83931801

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2212641.1A Ceased GB202212641D0 (en) 2022-08-31 2022-08-31 Novel compounds

Country Status (2)

Country Link
GB (1) GB202212641D0 (en)
WO (1) WO2024047135A1 (en)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636639A1 (en) 2013-10-10 2020-04-15 Araxes Pharma LLC Inhibitors of kras g12c
EA201792214A1 (en) 2015-04-10 2018-01-31 Араксис Фарма Ллк COMPOUNDS OF SUBSTITUTE QUINAZOLINE
JP6789239B2 (en) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Condensation tricyclic inhibitor of KRAS and method of its use
EP3325447A1 (en) 2015-07-22 2018-05-30 Araxes Pharma LLC Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
US11434231B2 (en) * 2015-07-22 2022-09-06 The Royal Institution For The Advancement Of Learn Substituted imidazoles for the treatment of cancer
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
AU2017266911B2 (en) 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
BR112019012976A2 (en) 2016-12-22 2019-12-31 Amgen Inc kras g12c inhibitors and methods of using them
JOP20190186A1 (en) 2017-02-02 2019-08-01 Astellas Pharma Inc Quinazoline compound
WO2018206539A1 (en) 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
JP2020521741A (en) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Compounds for the treatment of cancer and methods of their use
KR20200010306A (en) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Covalent Inhibitors of KRAS
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
UA125802C2 (en) 2017-11-15 2022-06-08 Міраті Терапьютікс, Інк. Kras g12c inhibitors
TW201938561A (en) 2017-12-08 2019-10-01 瑞典商阿斯特捷利康公司 Chemical compounds
TW201942116A (en) * 2018-02-09 2019-11-01 美商輝瑞股份有限公司 Tetrahydroquinazoline derivatives useful as anticancer agents
PL3886991T3 (en) 2019-12-11 2022-11-21 Eli Lilly And Company Kras g12c inhibitors

Also Published As

Publication number Publication date
WO2024047135A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
GB202319938D0 (en) Novel compounds
GB202319820D0 (en) Novel compounds
GB202318867D0 (en) Novel compounds
GB202318866D0 (en) Novel compounds
GB202318175D0 (en) Novel compounds
GB202317236D0 (en) Novel compounds
GB202316972D0 (en) Novel compounds
GB202316971D0 (en) Novel compounds
GB202316974D0 (en) Novel compounds
GB202316973D0 (en) Novel compounds
GB202316975D0 (en) Novel compounds
GB202315015D0 (en) Novel compounds
GB202310221D0 (en) Novel compounds
GB202310218D0 (en) Novel compounds
GB202308148D0 (en) Novel compounds
GB202308147D0 (en) Novel compounds
GB202307972D0 (en) Novel compounds
GB202307797D0 (en) Novel compounds
GB202307426D0 (en) Novel compounds
GB202307427D0 (en) Novel compounds
GB202305813D0 (en) Novel compounds
GB202305812D0 (en) Novel compounds
GB202304448D0 (en) Novel compounds
GB202302686D0 (en) Novel compounds
GB202302534D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)